Ava Nasrolahi1,2, Fatemeh Javaherforooshzadeh2, Mohsen Jafarzadeh-Gharehziaaddin3, Javad Mahmoudi4, Khadijeh Dizaji Asl5, Zahra Shabani6,7. 1. Infectious Ophthalmologic Research Center, Imam Khomeini Hospital Clinical Research Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 2. Pain Research Center, Imam Khomeini Hospital Clinical Research Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 3. Department of Education and Psychology, University of Aveiro, Aveiro, Portugal. 4. Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Golgasht Street, Azadi Avenue, Tabriz, Iran. 5. Department of Anatomical Science, Tabriz University of Medical Sciences, Tabriz, Iran. 6. Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Golgasht Street, Azadi Avenue, Tabriz, Iran. zh.shabani67@gmail.com. 7. Department of Neuroscience, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. zh.shabani67@gmail.com.
Abstract
INTRODUCTION: Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia among the elderly population. AD is accompanied with the dysregulation of specific neurotrophic factors (NTFs) and their receptors, which plays a critical role in neuronal degeneration. NTFs are small proteins with therapeutic potential for human neurodegenerative diseases. These growth factors are categorized into four families: neurotrophins, neurokines, the glial cell line-derived NTF family of ligands, and the newly discovered cerebral dopamine NTF/mesencephalic astrocyte-derived NTF family. NTFs are capable of preventing cell death in degenerative conditions and can increase the neuronal growth and function in these disorders. Nevertheless, the adverse side effects of NTFs delivery and poor diffusion of these factors in the brain restrict the efficacy of NTFs therapy in clinical situations. MATERIALS AND METHODS: In this review, we focus on the current advances in the use of NTFs to treat AD and summarize previous experimental and clinical studies for supporting the protective and therapeutic effects of these factors. CONCLUSION: Based on reports, NTFs are considered as new and promising candidates for treating AD and AD-associated cognitive impairment.
INTRODUCTION: Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia among the elderly population. AD is accompanied with the dysregulation of specific neurotrophic factors (NTFs) and their receptors, which plays a critical role in neuronal degeneration. NTFs are small proteins with therapeutic potential for human neurodegenerative diseases. These growth factors are categorized into four families: neurotrophins, neurokines, the glial cell line-derived NTF family of ligands, and the newly discovered cerebral dopamine NTF/mesencephalic astrocyte-derived NTF family. NTFs are capable of preventing cell death in degenerative conditions and can increase the neuronal growth and function in these disorders. Nevertheless, the adverse side effects of NTFs delivery and poor diffusion of these factors in the brain restrict the efficacy of NTFs therapy in clinical situations. MATERIALS AND METHODS: In this review, we focus on the current advances in the use of NTFs to treat AD and summarize previous experimental and clinical studies for supporting the protective and therapeutic effects of these factors. CONCLUSION: Based on reports, NTFs are considered as new and promising candidates for treating AD and AD-associated cognitive impairment.
Authors: Raymond T Bartus; Tiffany L Baumann; Lamar Brown; Brian R Kruegel; Jeffrey M Ostrove; Christopher D Herzog Journal: Neurobiol Aging Date: 2012-08-24 Impact factor: 4.673